appScorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Shilpa Medicare Ltd
SHILPAMED
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Price
Price Upside
—
Earnings
Earnings Growth
—
Revenue
Rev. Growth
—
Company Profile
Shilpa Medicare Limited is engaged in the business of manufacturing of bulk drugs or active pharmaceutical ingredient (API) and intermediates, and wind power generation.
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
High Pledged Promoter HoldingLower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
Increased Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has increased by 3.44%
Recent NewsAll news
Shilpa Medicare subsidiary’s Karnataka facility clears GMP inspection
1 month ago•Business Standard
Stock Alert: JSW Steel, Delta Corp, Rail Vikas Nigam, Adani Power, Shilpa Medicare
1 month ago•Business Standard
Shilpa Medicare sizzles after Unicycive gets positive results in clinical trials of OLC
1 month ago•Business Standard
Recent EventsAll events
Reply to Clarification- Financial results
The Exchange had sought clarification from Shilpa Medicare Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed. | Download
The Exchange had sought clarification from Shilpa Medicare Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed. | Download
Clarification - Financial Results
Cash Dividend
Final • Div/Share: ₹ 1.1
Decreased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 5.62%